Fundraising FoxEyestem
8 known investors
Find your way into Eyestem
Sign up to see every warm intro you have to Eyestem
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eyestem team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eyestem is a cell therapy company developing a scalable platform for treating incurable diseases, with embedded manufacturing and quality processes. Its lead product, Eyecyte-RPE, is an RPE cell therapy for Dry Age-related Macular Degeneration (AMD) currently in a Phase 2 clinical trial.
Investors · 8
Also in the syndicate · 7
AlkemleadBiological EleadBiological E. LimitedleadBiological E. Limited (BE)leadKotakKotak Private EquityNatcolead
Funding
SEC filings, press & company announcements$6.4M disclosed across 1 round · 2022
- $6.4MSeries AAug 2022 · 3 sources
Alkem (lead), Biological E (lead), Biological E. Limited (lead), Biological E. Limited (BE) (lead), Natco (lead), Endiya Partners, Kotak, Kotak Private Equity
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Eyestem do?
- Eyestem is a cell therapy company developing a scalable platform for treating incurable diseases, with embedded manufacturing and quality processes. Its lead product, Eyecyte-RPE, is an RPE cell therapy for Dry Age-related Macular Degeneration (AMD) currently in a Phase 2 clinical trial.
- Who are Eyestem's investors?
- Eyestem's investors include Endiya Partners.
- How much funding has Eyestem raised?
- Eyestem has disclosed $6.4M raised across 1 round.